Consistently with the bevacizumab mechanism of action, tumoural VEGF‐A expression and microvessel density (MVD), evaluated by IHC using the expression of the endothelia marker CD31, showed potential predictive value in retrospective tumour biomarker analyses of the GOG‐0218 trial.74 This evidence concerns the gene VEGFA and neoplasm.